In the fight against Alzheimer's disease, the next breakthrough might not come from an expensive new drug — it could come from a simple, inexpensive supplement you can already buy over the counter.
Arginine: A Surprisingly Simple Solution
Researchers from Kindai University in Japan have discovered that arginine, a naturally occurring amino acid, can significantly reduce the buildup of toxic amyloid-β proteins in the brain — the hallmark of Alzheimer's disease.
Published in Neurochemistry International, the study found that arginine acts as a chemical chaperone, helping proteins maintain their proper shape and preventing the misfolding that leads to harmful aggregation.
What the Study Found
In laboratory experiments, arginine blocked the formation of Aβ42 aggregates — the most toxic form of amyloid protein. The effect increased with higher concentrations.
When tested in animal models of Alzheimer's disease (both fruit fly and mouse models), oral arginine treatment:
- Reduced amyloid plaque levels in the brain
- Lowered insoluble Aβ42 — the most harmful form
- Improved behaviour in cognitive tests
- Reduced neuroinflammation by suppressing pro-inflammatory gene activity
Why It's Exciting
Current antibody-based Alzheimer's treatments can cost tens of thousands of pounds per year and may trigger serious immune-related side effects. Arginine, by contrast, is already considered clinically safe, is widely available as a dietary supplement, and costs just pennies per dose.
Professor Yoshitaka Nagai explained: "What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for Alzheimer's disease."
Important Caveats
The researchers emphasised that the doses and methods used in this study were specifically designed for research and are not the same as commercial supplements. Human clinical trials would be needed before any treatment recommendations can be made.
Still, with approximately 55 million people living with dementia worldwide, the potential for a safe, affordable intervention is enormously hopeful.
Sources: Kindai University, ScienceDaily, Neurochemistry International (May 4, 2026)
